Physician profile
Robert Lamberg
NPI 1811993710
$2,157.75
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $432 · 2021: $911 · 2022: $12.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $690.72 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $368.63 | 2019-2022 | |
| Allergan, INC. | $358.83 | 2019-2021 | |
| Alcon Vision LLC | $242.64 | 2019-2021 | |
| Biotissue Holdings INC. | $222.75 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $160.72 | 2019-2021 | |
| Shire North American Group INC | $49.20 | 2019 | |
| Sun Pharmaceutical Industries INC. | $32.57 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $16.88 | 2020 | |
| Omeros Corporation | $14.81 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lamberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.